Pharmaceutical Working Group Meeting Go back »
-
Time2006-06-16 | 14:00
-
Venue:European Chamber Office, Beijing & Shanghai
-
Address:S-123 Beijing Lufthansa Center, 50 Liangmaqiao Road
-
Fee:Members: FREE |
Non Members: FREE
The European chamber is pleased to invite you to a Pharmaceutical Working Group Meeting on Friday, 16th June 2006. The meeting will be held simultaneously in European Chamber Offices in Beijing and Shanghai.
To confirm your attendance please contact Rhian Kelly at rhiankelly@euccc.com.cn.
Kindly note that the meeting is open for members only. For Further information about Working Group or how to become a member, please contact Business Manager Mr. David Lee (dlee@euccc.com.cn) in Beijing or Mr. Tony Brooks (tbrooks@euccc.com.cn) in Shanghai.
Event review
Pharmaceutical Working Group MeetingFriday, 16th June 2006, 2:00 p.m.
European Chamber Office, Beijing & Shanghai
Participants:
Beijing
Company |
Name |
Chamber Member |
CJB China Ltd |
Christopher J. Baron |
X |
PWC |
Beatrijs Van Liedekerke |
X |
GSK |
Bryan Xue |
X |
Ipsen |
Eric Bouteiller |
X |
Development Solutions |
Angus Lambkin |
|
EU Chamber |
Ms. Rhian Kelly |
X |
Solvay |
Christian Grapow |
X |
EU Chamber |
Caroline Bevernage |
X |
EU Chamber |
Tracy Yanjun Zhang |
X |
RDPAC |
Peter Scheuer |
X |
AstraZeneca |
Steen Kroyer |
X |
EU Delegation |
Olivier Micol |
X |
Shanghai
Company |
Name |
Chamber Member |
Annie, Zhu Huimin |
DSM Anti-Infectives |
X |
Markus Barner |
Boehringer Ingelheim |
X |
EU Chamber |
Berenice Voets |
X |
EU Chamber |
Maurizio Andreano |
X |
Agenda
1. Position Paper 2006 – review draft
2. EC Public consultation on a strategy for the trade and economic relations between EU and China
3. Update on MA Workshop
4. Import / Distribution of Finished Pharmaceuticals
5. Discussion on industrial and scientific dialogue
6. Issue of “liaison offices”
Discussion points
1. Position Paper 2006 – review draft
The deadlines for the 2006 Position Paper are as follows:
- Thursday 22nd June, Rhian Kelly will circulate the final draft of the Position Paper to the Chair/Vice-Chair
- Monday 26th June, the final draft will be circulated to all members for comments
- The English version has to be finalised by 30th June
- The Chinese version has to be finalised by 31st July
The points raised during discussion will be included in the revised draft of the Position Paper.
2. EC Public consultation on a strategy for trade and economic relations between the EU and China
The European Commission is trying to reassess the EU-China trade and investment relationship for the next 5-10 years. Beyond this the current EU-China Framework Agreement is outdated and a much boarder agreement, with better focus on trade and investment, and emerging sectors would be a benefit. Therefore the European Commission has asked for input on the opportunities and challenges from stakeholders. This process of consultation will come together on 7th July a high-level conference will be held in Brussels. The broader Framework Agreement will be discussed with Chinese counterparts at the EU-China Summit in September.
Different organisations have already communicated their recommendations to the European Commission. To view the EFPIA response to the consultation, please click here.
During Mandeslon’s visit last week, the European Chamber held an industry briefing and provided Mandelson with some recommendations. To view the response of the European Chamber to the EC Consultation, please click here.
Members discussed the overall trade picture for the pharmaceutical industry. It was suggested that at the next meeting there ought to be a presentation on the trade figures for the pharmaceutical. There should be a clear distinction between the import / export of raw material and finished products. The European Delegation will provide the exact data.
3. Update on MA Workshop
This workshop is currently scheduled to take place on Thursday 21st September 2006 will be held in the week and aims to establish long-term cooperation with the SFDA in order to facilitate the establishment of a market authorization system all over China which would lead to toll manufacturing, co-manufacturing, co-promotion and co-marketing. There will be a large EFPIA delegation coming to China and so there will be a number of meetings held with stakeholders in China.
4. Import/Distribution of Finished Pharmaceuticals
Members observed some progress over the last few months but there is still the need for more. RDPAC is drafting a memo for members to explain the procedures for all foreign pharmaceutical companies in China. This will circulated shortly.
5. Discussion on industrial and scientific dialogue
The Working Group is keen to initiate an innovative and scientific dialogue with Chinese authorities. The idea is to support policy work being done to shape the future of the industry. This means engaging MOST, leading academics and institutions. Once identified the following action can be taken:
- Presentation by the European Chamber of the 2006 Position Paper to NDRC and MOST in order to kick-off dialogue
- Design a collaboration project
Regarding the Chinese authorities, there are two targets: NDRC (not price people) and MOST (for scientific innovation).
Olivier Micol will put us in contact with the Councellor of Science and Technology at the European Delegation, who is invited to the next working group meeting to present san overview of S&T to members.
Members raised questions about government funding for pharmaceutical R&D. In Shanghai, tax policy is used to encourage R&D.
Wang Ping, Tracy Yanjun and Bryan Xue will meet to identify the key officials of the pharmaceutical sector. At this stage there is no “pharmaceutical policy department”. Moreover, there is no specific organization to take care of future innovation (R&D).
This could be a key recommendation for next year.
6. Issue of “Liaison Offices”
There are new regulations governing the registration and renewal of liaison offices. Currently SAIC no longer requires registration of liaison offices. Hiring staff would now go through HQ and operating issues should be eliminated. However according to members of the Chamber, 5 main issues still remain:
1) Disparities in how the regulations are interpreted and implemented at local level
2) Operating without registration poses a number of compliance and tax-related challenges
3) The definition of the term “operational activities” is unclear and is subsequently open to misinterpretation
4) It is unclear what is required for branch offices
5) Concerns related to the lack of transparency and public consultation
To view different articles related to this issue of Liaison Offices, please click here and click here.
Members asked to discuss this at the next meeting and wanted to have clear answers on the issue of liaison offices. The Chamber will notify members of the WG when the Legal and Finance & Taxation WGs next meet to discuss this issue.
7. Next Meeting
The next Pharmaceutical Working Group meeting will be held on Friday 15th September 2006 at the European Chamber offices in Beijing and Shanghai from 2 to 4pm.
Interested in this topic?
Join the following working groups and fora to get more information and receive regular updates.